Axsome Therapeutics (NASDAQ: AXSM) has been a zero-to-hero biotech stock. It's still a company with a lot of potential, though -- it has four leading treatment candidates in its pipeline, all with high chances of earning regulatory approval. It announced top-line clinical trial results on AXS-05 for the treatment of depression (phase 2), AXS-07 for the treatment of migraine headaches (phase 3), and AXS-12 for the treatment of narcolepsy (phase 2).
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting